Want to see SCNI full AI Analyst Report?
SCNI Stock Chart & Stats
$2.87
-$0.02(-6.92%)
At close: 4:00 PM EDT
$2.87
-$0.02(-6.92%)
Day’s Range― - ―
52-Week Range$0.66 - $15.49
Previous CloseN/A
Volume35.26K
Average Volume (3M)4.43M
Market Cap
$427.52K
Enterprise Value$7.79M
Total Cash (Recent Filing)$2.85M
Total Debt (Recent Filing)$3.58M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-62161.60
Shares Outstanding706,586
10 Day Avg. Volume6,769,712
30 Day Avg. Volume4,430,977
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.21
Price to Sales (P/S)1.27
P/FCF Ratio-0.27
Enterprise Value/Market Cap18.23
Enterprise Value/Revenue5.22
Enterprise Value/Gross Profit-2.07
Enterprise Value/Ebitda-1.17
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
CDMO Contract GrowthThe $5.1 million agreement materially increases contracted CDMO work and extends revenue visibility across 2026 and 2027. It can improve facility utilization, support working capital through milestone payments, and deepen Scinai’s position in outsourced clinical development and manufacturing.
Growing Order BacklogA substantially larger committed-order base provides a stronger foundation for scaling the two-site CDMO platform than the prior year. If delivered on schedule, these projects can support recurring customer relationships, better utilization, and improved operating leverage over the next several quarters.
Expanded CDMO CapabilitiesThe acquired Yavne operations broaden Scinai’s service offering beyond its Jerusalem capabilities, combining chemistry development and small-scale API manufacturing with biologics and clinical manufacturing. This integrated platform may help win higher-value programs and support longer customer engagements.
Bears Say
Persistent Operating LossesThe current cost base is still far above revenue, so commercial growth has not yet translated into operating profitability. Until utilization rises and contracted work is recognized, recurring gross and operating losses could continue consuming capital and limit investment in proprietary programs.
Cash Burn And Funding NeedConsistently negative operating and free cash flow means Scinai cannot currently fund operations internally. The modest cash balance and stated need for additional capital leave execution dependent on customer receipts, non-dilutive funding, or further financing, increasing financial pressure during scale-up.
Dilution And Financing RiskRecent financing strengthens liquidity but adds warrant overhang, while use of the SEPA would issue securities at a discount to VWAP. Further equity issuance could dilute existing holders and may remain necessary if CDMO cash generation or customer payments fall short of management’s plans.
Scinai Immunotherapeutics News
SCNI FAQ
What was Scinai Immunotherapeutics’s price range in the past 12 months?
Scinai Immunotherapeutics lowest stock price was $0.66 and its highest was $15.49 in the past 12 months.
What is Scinai Immunotherapeutics’s market cap?
Scinai Immunotherapeutics’s market cap is $427.52K.
When is Scinai Immunotherapeutics’s upcoming earnings report date?
Scinai Immunotherapeutics’s upcoming earnings report date is Dec 02, 2026 which is in 43 days.
How were Scinai Immunotherapeutics’s earnings last quarter?
Scinai Immunotherapeutics released its earnings results on Aug 20, 2026. The company reported -$3.662 earnings per share for the quarter.
Is Scinai Immunotherapeutics overvalued?
According to Wall Street analysts Scinai Immunotherapeutics’s price is currently Overvalued.
Does Scinai Immunotherapeutics pay dividends?
Scinai Immunotherapeutics does not currently pay dividends.
What is Scinai Immunotherapeutics’s EPS estimate?
Scinai Immunotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scinai Immunotherapeutics have?
Scinai Immunotherapeutics has 706,586 shares outstanding.
What happened to Scinai Immunotherapeutics’s price movement after its last earnings report?
Scinai Immunotherapeutics reported an EPS of -$3.662 in its last earnings report. Following the earnings report the stock price went up 7.338%.
Which hedge fund is a major shareholder of Scinai Immunotherapeutics?
Currently, no hedge funds are holding shares in SCNI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing NanoAb applications for various other disease indications. Established in 2003, the company was formerly known as BiondVax Pharmaceuticals Ltd. before rebranding to Scinai Immunotherapeutics Ltd. in September 2023. Its corporate headquarters are situated in Jerusalem, Israel.
Technical Analysis
Ownership Overview
― Insiders
―
Mutual Funds
0.37% Other Institutional Investors
99.63% Public Companies and
Individual Investors